Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

@article{Bruserud2007HistoneDI,
  title={Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.},
  author={\Oystein Bruserud and Camilla Stapnes and Elisabeth Ersvaer and Bj\orn Tore Gjertsen and Anita Ryningen},
  journal={Current pharmaceutical biotechnology},
  year={2007},
  volume={8 6},
  pages={388-400}
}
Characterization of epigenetic events in carcinogenesis has led to the discovery of a new class of oncogenes and thereby a new class of therapeutic targets. Among the new therapeutic approaches are modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). HDACs deacetylate histones as well as transcription factors and can modulate gene expression through both these mechanisms in normal and malignant cells. Furthermore, acetylation is an important… CONTINUE READING
45 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

Similar Papers

Loading similar papers…